Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oditrasertib

Next Previous
X
Search
Drug Profile

Oditrasertib

Alternative Names: C19061501-F; DN-0002489; DN-2489; DNL-788; RA15804589; SAR 443820

Latest Information Update: 16 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Harvard University
  • Developer Denali Therapeutics Inc; Sanofi
  • Class Antidementias; Small molecules
  • Mechanism of Action RIPK1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple sclerosis
  • No development reported Alzheimer's disease
  • Discontinued Amyotrophic lateral sclerosis

Most Recent Events

  • 07 Mar 2024 Sanofi terminates a Phase-II clinical trials in Amyotrophic lateral sclerosis (In the elderly, In adults) in Japan, Poland, Belgium, Spain Canada, China, France, Germany, US, Netherlands, United Kingdom, Sweden, Italy and USA (PO) due to unachieved primary endpoint(NCT05237284) (EudraCT2021-004156-42)
  • 23 Feb 2024 Discontinued - Phase-I for Amyotrophic lateral sclerosis (In volunteers) in USA (PO) prior to February 2024
  • 23 Feb 2024 Discontinued - Phase-II for Amyotrophic lateral sclerosis (In the elderly, In adults) in Spain, Belgium, United Kingdom, Netherlands, Germany, France, Canada, USA, China, Italy, Sweden, Japan, Poland (PO) prior to February 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top